Incidence of cGVHD after allogeneic BMT.

All patients who survived until day 100 (n = 82) were divided into 3 groups according to the numbers of CD4^bright DCs they received in the bone marrow allograft (Figure 3). Log-rank statistic comparing the incidence of cGVHD between recipients of smallest numbers of CD4^bright DCs (group 1_(DC), n = 29) versus the recipients of intermediate numbers of CD4^bright DCs (Group 2_(DC), n = 26) or the largest numbers of CD4^bright DCs (group 3_(DC), n = 27) was 4.2 (P = .04).